InvestSMART

Immuron Limited (ASX:IMC)

ALERT: Price-sensitive ASX Announcement for IMC
Current share price for IMC : $0.034 0.005 (17.24%)+
Announcement
Release
25 Feb 2026 3:49PM
Price at Release
$0.029
Full Release
download
Summary
Immuron Limited's Half Year Report for the period ending 31 December 2025 details a comprehensive review of financial performance and operational activities. The company reported an increase in revenue from ordinary activities by 4.8% to AUD 4,184,357, with a net loss of AUD 1,919,074, a 22.9% decrease compared to the previous period. Immuron's cash reserves significantly rose to AUD 9,995,328, and the net assets increased to AUD 13,076,439. The report highlights regulatory achievements including FDA approval for the Phase 2 clinical trial of IMM-529 for Clostridioides difficile infection and the launch of PROIBS® for IBS in Australia. Furthermore, it includes the development of novel therapeutics targeting gastrointestinal pathogens in collaboration with the US Department of Defense.
Key Points
  • Revenue from ordinary activities up 4.8% to AUD 4,184,357.
  • Net loss for half-year reduced to AUD 1,919,074.
  • Cash reserves increased to AUD 9,995,328.
  • Received FDA approval for IMM-529 Phase 2 clinical trial.
  • Launched PROIBS® for IBS treatment in Australia.
  • Collaboration with US Department of Defense on new therapeutics.
  • Net tangible asset backing per share is 3.94 cents.
  • No dividends declared for the period.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.